United Kingdom Chronic Obstructive Pulmonary Disease Treatment Market to be Dominated by Supermarkets and Hypermarkets
The increasing concern about pulmonary disease is
expected to drive the growth of United Kingdom chronic obstructive pulmonary
disease treatment market in the forecast period, 2024-2028.
According to TechSci Research report, “Chronic Obstructive Pulmonary Disease
Treatment Market
- By Region, Competition, Forecast and Opportunities, 2018-2028”, chronic obstructive pulmonary disease treatment market is anticipated
to grow at an impressive rate in the forecast period, 2024-2028. This
can be ascribed to the rising demand for effective medicine with medical
benefits such as improved lung function, and reduce exacerbations, enhanced
exercise capacity and reduced mortality along with growing preference for
inhalation device among people facing COPD related issues, across the region.
Additionally, rapid advances in science and technology, increasing healthcare
expenditure, changes in lifestyle, burgeoning aging population, and rising
smoke and pollution through cigarettes and different activities will escalate
the growth of United Kingdom chronic obstructive pulmonary disease treatment market
in coming years. Besides, the emergence of new products such as triple therapy
inhalers, biologic therapies, digital health solutions and anti-inflammatory
agents will further be expected to support the United Kingdom chronic
obstructive pulmonary disease treatment market growth.
However, the disease burden of chronic obstructive
pulmonary disease treatment in United Kingdom can be high, and COPD imposes a
significant burden on healthcare systems due to its chronic and progressive
nature which can slowing down the growth of United Kingdom chronic obstructive
pulmonary disease treatment market in the forecast period. Similarly, despite
efforts to raise awareness, COPD remains underdiagnosed and often misdiagnosed.
Many individuals with COPD may not seek medical attention until the disease has
progressed, leading to delayed diagnosis and intervention which may hamper the United
Kingdom chronic obstructive pulmonary disease treatment market growth during
the forecast period. Also, some individuals with COPD may face barriers to
accessing timely and appropriate care. Factors such as geographical location,
socioeconomic status, and healthcare disparities can impact access to
healthcare services, including specialist consultations, pulmonary
rehabilitation programs, and access to medications which can further restrict
the growth of United Kingdom chronic obstructive pulmonary disease treatment
market.
Browse over XX market data
Figures spread through XX Pages and an in-depth TOC on
" United Kingdom Chronic Obstructive Pulmonary Disease TreatmentMarket.”
The
United Kingdom chronic obstructive pulmonary disease treatment market can be
segmented by treatment type, type, distribution channel, and by region.
Based on type, the United Kingdom chronic obstructive pulmonary
disease treatment market can be segmented into Chronic Bronchitis, Emphysema. The Chronic Bronchitis
Management segment dominated the market in 2022 and is expected to continue
maintaining its dominance throughout the forecast period. This can be ascribed
to increasing prevalence of smoking and environmental pollution-related
bronchial inflammation seen in chronic bronchitis. Furthermore, the emphasis on
smoking cessation and prevention measures in recent years may contribute to a
larger proportion of COPD patients presenting with chronic bronchitis drinks
across the region.
Based on distribution channel,
the market can be segmented into hospital
pharmacies, retail pharmacies, and online pharmacies. The hospital &
retail pharmacies segment is expected to dominate during the forecast period. The
hospital pharmacies play a significant role in the distribution of COPD
medications, particularly for patients admitted in hospitals or those requiring
specialized care whereas, retail pharmacies, including community pharmacies or
local pharmacies, are easily accessible to the general population. They are a common
distribution channel for COPD medications, especially for patients receiving
outpatient care or managing their condition in a non-acute setting.
Major companies operating in United
Kingdom chronic obstructive pulmonary disease treatment market are:
- GlaxoSmithKline (GSK) PLC
- AstraZeneca Ltd
- Boehringer Ingelheim GmbH
- Novartis Ltd
- Teva Pharmaceutical
Industries Ltd.
- Orion Pharma Ltd
- Vectura Group Ltd/United
Kingdom
In October 2021, GSK has
unveiled plans for a new consumer healthcare company's UK headquarters. In
addition to its long-term plan for the GSK headquarters, GSK unveiled designs
for a significant new UK-based headquarters and worldwide campus for the new
Consumer Healthcare company following its separation in 2022
In 2022, Affinivax, Inc., a
clinical-stage biopharmaceutical company, will be acquired by GSK for US$2.1
billion, plus up to US$1.2 billion in potential milestone payments. The most
cutting-edge vaccinations in this new class are next-generation pneumococcal
vaccines, which are being developed by Affinivax
Download Free Sample Report
Customers
can also request for 10% free customization on this report.
“United Kingdom chronic
obstructive pulmonary disease treatment market is expected to rise during the forecast period on account of
the rising demand for effective medications with medical benefits along with
growing preference for personalized treatment plans across the region.
Furthermore, trend of personalized medicine is growing, particularly among
individuals with COPD-related medical conditions, where generic treatment is specific
which will further contribute to the demand for United Kingdom chronic
obstructive pulmonary disease treatment market during the forecast period.
Besides, increasing concern about healthy lifestyles and increasing expenditure
on health and wellness is further expected to create lucrative opportunities
for the market growth.” said Mr. Karan Chechi, Research Director with TechSci
Research, a research based global management consulting firm.
“United
Kingdom Chronic Obstructive Pulmonary Disease Treatment Market by Treatment
Type (Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiester
Type 4 Inhibitor, Mucokinetics, and Others), By Type (Chronic Bronchitis,
Emphysema), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and
Online Pharmacies), By Region, Competition, Forecast and Opportunities, 2028”, has evaluated the future
growth potential of United Kingdom chronic obstructive pulmonary disease
treatment market and provides statistics & information on market size,
structure, and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in United Kingdom chronic
obstructive pulmonary disease treatment market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com